About This Event

Prime Medicine (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying Prime Editing technology, visits the Nasdaq MarketSite in Times Square.

In honor of the occasion, Andrew Anzalone, M.D. Ph.D., Co-Founder and Head of Prime Editing Platform, rings the Opening Bell.